Thea M. Mooij

Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · JAMA · 2017 · 2.9K citations · Full text

Medicine, Genetics, Oncology +17

Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis

B.A.M. Heemskerk-Gerritsen, Matti A. Rookus, Cora M. Aalfs et al. · International Journal of Cancer · 2014 · 213 citations · Full text

Medicine, Oncology, Breast Oncology +14

Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort

Flora E. van Leeuwen, Helen Klip, Thea M. Mooij et al. · Human Reproduction · 2011 · 198 citations · Full text

Medicine, Gynecology, Oncology +17

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

Brenda Hermsen, R.I. Olivier, René H.M. Verheijen et al. · British Journal of Cancer · 2007 · 153 citations · Full text

Medicine, Gynecology, Oncology +17

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Daniel R. Barnes, Matti A. Rookus, Lesley McGuffog et al. · Genetics in Medicine · 2020 · 145 citations · Full text

Life Sciences, Genetics, Oncology +17